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Abstract 
We reported earlier the diagnostic potential of a melanogenic vaccinia virus based system in 
magnetic resonance (MRI) and optoacoustic deep tissue imaging (MSOT). Since melanin over-
production lead to attenuated virus replication, we constructed a novel recombinant vaccinia virus 
strain (rVACV), GLV-1h462, which expressed the key enzyme of melanogenesis (tyrosinase) 
under the control of an inducible promoter-system. In this study melanin production was detected 
after exogenous addition of doxycycline in two different tumor xenograft mouse models. Fur-
thermore, it was confirmed that this novel vaccinia virus strain still facilitated signal enhancement 
as detected by MRI and optoacoustic tomography. At the same time we demonstrated an en-
hanced oncolytic potential compared to the constitutively melanin synthesizing rVACV system. 
Key words: Oncolysis, Molecular Imaging, Reporter gene, virotherapy 
Introduction 
Early detection of cancer facilitates early treat-
ment and a better success rate for therapy. Conse-
quently, a number of different applications to detect 
cancer cells are currently in development or already in 
daily clinical use. One option is the serological diag-
nosis of tumor biomarkers (e.g. alpha-fetoprotein 
(AFP) as a marker for hepatocellular carcinoma [1], 
prostate specific antigen (PSA) for prostate cancer [2] 
or the carcinogenic embryonic antigen (CEA) for dif-
ferent cancer types [3]). However, due to 
false-positive as well as false-negative results these 
serological tests require confirmation by tissue biop-
sies or direct imaging techniques. Imaging modalities 
that are currently used for cancer detection include 
computed tomography (CT), ultrasound, nuclear im-
aging modalities such as single-photon emission 
computer tomography (SPECT) and positron emis-
sion tomography (PET), as well as magnet resonance 
imaging (MRI). More recently (multispectral) optoa-
coustic tomography (MSOT) [4] is developed as an-
other tool that will allow clinicians to detect tumors 
and their metastases [5,6]. 
In an earlier publication we could show that 
melanin is an excellent reporter for both MRI as well 
as MSOT [7]. Melanin can be produced upon expres-
sion of the melanogenic enzyme tyrosinase (Tyr) and 
tyrosinase-related protein 1 (TYRP1) [7]. While the 
ability of melanin to bind free metal ions [8] leads to 
an intense MRI signal, presence of melanin also gen-
erated specific signals using MSOT due to its high 
absorption coefficient in the near infrared optical 
window [7,9,10]. It was shown that recombinant vac-
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cinia virus strains (rVACVs) encoding melanogenic 
enzymes had great theranostic potential [7]. However, 
the constitutive production of melanin resulted in 
decelerated viral replication of the melanogenic 
rVACV strains and therefore the therapeutic potential 
was diminished when compared to the 
non-melanogenic parental rVACV strain GLV-1h68.  
Here, we enhanced the therapeutic potential of 
melanogenic rVACV by constructing a new melano-
genic vaccinia virus strain (GLV-1h462) that encodes 
the melanogenic tyrosinase under control of an in-
ducible promoter-system. We confirmed melanin 
production after exogenous induction in tumor bear-
ing mice and analyzed the underlying kinetics. Fur-
thermore, we could show that this new strain retained 
its imaging capabilities but at the same time had en-
hanced oncolytic potential compared to a constitu-
tively melanin producing rVACV control strain. The 
synergistic effects of therapy and diagnosis of the 
melanogenic rVACV were therefore improved by 
taking advantage of the inducible promoter-system. 
Materials and Methods 
Cell cultures and infection experiments 
The cell lines A549 and PANC-1 (obtained from 
the American Culture Collection) were cultured in 
RPMI 1640 (Sigma-Aldrich, Schnelldorf, Germany) 
and DMEM (Sigma-Aldrich), respectively, supple-
mented with 10% fetal bovine serum (FBS; PAA, 
Cölbe, Germany) and 1% 100 × penicillin (10000 
units/ml)/streptomycin (10 mg/ml) (PAA). The cul-
tures were incubated in a humidified incubator at 
37°C and 5% CO2 atmosphere. 
One day prior to infection, A549 or PANC-1 
cancer cells were seeded into 6 or 24 well plates to 
achieve 90% - 95% confluence at the day of infection. 
The cells were infected with different rVACVs at dif-
ferent MOIs in infection medium (RPMI 1640 or 
DMEM + 2% FBS and 1% penicillin/streptomycin). 
After incubation for 1h, the infection medium was 
replaced with fresh growth medium (RPMI 1640 or 
DMEM + 10% FBS + 1% penicillin/streptomycin).  
Construction of an rVACV strain with induci-
ble tyrosinase expression 
The codon optimized tetR sequence was ampli-
fied with primers tetR-5 and tetR-3 from the template 
FH1tUTG [11] (courtesy of Dr. M. Herold), and the 
PCR product was cloned into the pCRII-Blunt-TOPO 
vector (Invitrogen). All primer and promoter se-
quences are listed in Supplementary Table S1. After 
sequence verification, the tetR cDNA was cut out with 
Xho I and BamH I, and ligated into pSC65 [12] with 
the same cuts, thus placing the tetR gene under the 
control of vaccinia virus promoter p7.5. The p7.5-tetR 
expression cassette was released by Hind III and 
BamH I, and subsequently put into the vaccinia virus 
transfer vector for F14.5L locus as in the final con-
struct Fp7.5-tetR. The tetR cDNA under the control of 
vaccinia virus strong synthetic early/late promoter 
(SEL) was constructed by ligating the Xho I/Sal I 
fragment of tetR from Fp7.5-tetR to a FSEL vector 
precut with Sal I. The Fp7.5-tetR and FSEL-tetR were 
used to introduce tetR gene into the virus genome.  
To add tetO to CBG-2A-mRFP and mTyr, respec-
tively, the primer pairs tetO-mRFP-5 / mRFP-3 and 
tetO-mTyr-5 / mTyr-3 were used to amplify the target 
cDNAs from constructs containing CBG-2A-mRFP 
and mTyr. The PCR products were cloned into the 
pCRII-Blunt-TOPO vector. The tetO-CR (te-
tO-CBG-2A-mRFP) and tetO-mTyr cDNAs were re-
leased by Sal I and Pac I from pCRII-tetO-CR and 
pCRII-tetO-mTyr, and ligated to the vaccinia virus 
transfer vectors for the TK locus with the same cuts, 
placing the tetO containing cDNAs under the control 
of vaccinia virus strong synthetic late promoter SL 
resulting in TK-SL-tetO-CR and TK-SL-tetO-mTyr, 
which were used for the generation of recombinant 
viruses.  
All virus strains were constructed using a selec-
tion process that is dependent on the expression of 
guanine phosphoribosyltransferase [13]. 
Virus strains 
The tyrosinase-negative strains GLV-1h68 [14] 
and GLV-1h312 [15] were used as non-melanogenic 
control viruses. The strain GLV-1h460 encodes the 
main melanogenic enzyme mTyr under control of the 
synthetic late promoter followed by the tet-operator 
sequence tetO. Due to the absence of the tet-repressor 
TetR, the expression is not inhibited and occurs in the 
late phase of the viral replication cycle. In contrast, 
GLV-1h462 encodes TetR under control of the syn-
thetic early-late promoter, which should lead to the 
presence of the regulator protein during the whole 
infection cycle. Consequently, the mTyr expression 
should only occur in the presence of doxycycline, 
when TetR dissociates from the tet-operator sequence 
[16]. 
Western blot analysis 
A549 cancer cells were infected with GLV-1h312, 
GLV-1h460 and GLV-1h462 respectively, at an MOI of 
0.1 in the presence or absence of doxycycline (1 
µg/ml). After one day, the medium was aspirated and 
the cell layer lysed in SDS sample buffer, transferred 
to fresh 1.5 ml tube and heated to 99°C for 10 min. 
Protein lysates were separated by 10% 
SDS-Polyacrylamide gel electrophoresis and trans-
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ferred onto a nitrocellulose membrane (Whatman 
GmbH, Dassel, Germany). After blocking, the mem-
brane was incubated with anti-human-tyrosinase goat 
polyclonal antibody (sc-7833, Santa Cruz Biotechnol-
ogy Inc, Santa Cruz, USA), anti-beta-glucuronidase 
rabbit polyclonal antibody (G5420, Sigma-Aldrich), 
anti-beta-actin mouse monoclonal antibody (ab6276, 
Abcam, Cambridge, UK), anti-RFP rabbit polyclonal 
antibody (AB231, Evrogen, Moscow, Russia), an-
ti-GFP rabbit polyclonal antibody (sc-8334, Santa Curz 
Biotechnology Inc) and anti-TetR mouse monoclonal 
antibody (Clone 9G9, Clontech, Mountain View, USA) 
respectively. The protein bound primary antibodies 
were detected using horseradish peroxidase conju-
gated rabbit anti-mouse (ab6728, Abcam), goat an-
ti-rabbit (ab6721, Abcam) or rabbit anti-goat 
(ab6741-1, Abcam) secondary antibodies, followed by 
enhanced chemiluminescence detection with the mo-
lecular imager ChemiDox XRS+ from Bio Rad (Bio 
Rad, Munich, Germany). 
Cytotoxicity assay  
A549 or PANC-1 tumor cells were seeded in 24 
well plates and infected at ~ 95% confluence with an 
MOI of 0.01 (A549) or MOI 0.1 (PANC-1). At each 
point, supernatant was discarded and cell layer cov-
ered with 250µl of a 2.5mg/ml Methylthiazolyldi-
phenyl-tetrazolium bromide (MTT; M2128, Sig-
ma-Aldrich) solution. After incubation for 2h at 37°C 
the supernatant was discarded, the formazan crystals 
resolved in 1 N HCl/isopropyl alcohol and the optical 
density at 570nm determined. Afterwards, the relative 
survival was calculated related to uninfected controls, 
which were considered as 100% at each time point. 
Viral replication assay 
To compare the replication of GLV-1h462 in the 
presence or absence of doxycycline (1µg/ml) a 
standard plaque assay was performed. Therefore, 
A549 or PANC-1 tumor cells were seeded into a 24 
well plate, incubated to a confluence of ~ 95% and 
infected with the non-melanogenic rVACV GLV-1h68 
as a control and the inducible melanogenic 
GLV-1h462 at MOI 0.01 (A549) or MOI 0.1 (PANC-1). 
One triplicate of each group at each time point was 
incubated with 1µg/ml doxycycline while one was 
incubated without doxycycline. 24, 48 and 72 hours 
post viral infection (hpvi) samples were collected and 
stored at -20°C. A standard plaque assay [17] was 
performed to obtain the viral titers (plaque forming 
units per milliliter [pfu/ml]) at each time point. 
ß-gucuronidase assay 
All rVACV strains in this study encode the 
Escherichia coli ß-glucuronidase gene gusA. The gene 
product is not secreted and released only upon cell 
lysis. Therefore, the concentration of glucuronidase in 
the blood can be used as a marker for viral replication 
and oncolysis. The ß-glucuronidase activity can be 
determined as previously reported [18]. 
Plaque Size measurements 
A549 lung carcinoma cells, PANC-1 human 
pancreatic tumor cells or CV-1 cells were infected 
with the upon induction tyrosinase expressing 
GLV-1h462, the constitutively tyrosinase expressing 
GLV-1h460 and the non-melanogenic GLV-1h312. 
After 1h infection the cells were covered with medium 
containing 1.5% (w/v) carboxymethylcellulose (Sig-
ma-Aldrich) with or without doxycycline (1 µg/ml). 
In some experiments, medium containing carbox-
ymethylcellulose with doxycycline was replaced with 
the same medium without dox after a single wash 
with 1 ml PBS. After two or three days of infection cell 
layers were stained with crystal violet and plaques 
photographed with an Axiovert 200 M microscope 
equipped with a digital AxioCam MRc5 (Zeiss, Jena, 
Germany) camera and the Axiovision 4.5 software. 
For each group, the maximal diameters of 25 to 104 
plaques were determined using Image J 1.47v. 
Blood sample collection 
To determine the virus mediated oncolysis by 
measuring the E. coli ß-glucuronidase activity, blood 
was taken 56 days post rVACV injection. Whole blood 
was collected in BD Microtainer SST tubes (BD Bio-
science, Heidelberg, Germany) and allowed to coag-
ulate on ice, followed by a centrifugation step at 13000 
rpm for 20 min at 4°C to separate blood cells from 
serum. The serum was stored at -80°C until usage. 
Animal studies 
A549 or PANC-1 xenograft tumors were devel-
oped in 6- to 8- week-old female or male nude mice 
(Athymic Nude Foxn1nu, Harlan, Borchem, Germany 
and Livermore, USA) by implanting 5 × 106 A549 cells 
or 4 x 106 PANC-1 cells subcutaneously in the right 
hind flank. Fourteen days after A549 tumor cell im-
plantation, a single dose of PBS, or 5 × 106 plaque 
forming units (pfu) of a not tyrosinase expressing 
control virus strain, GLV-1h460 or GLV-1h462 in 100 
μL of PBS was injected into a lateral tail vein of mice. 
PANC-1 xenograft bearing athymic nude mice were 
systemically injected under isoflurane narcosis by 
administration of 100 µl rVACV suspensions into the 
retro-orbital sinus vein at an average tumor volume of 
about 200 mm³. Weights of the mice and tumor 
growth, in two dimensions using a digital caliper, 
were recorded once a week. Tumor volume was cal-
culated with the formula ([length × width2] × 0.52). 
For induction of tyrosinase expression in GLV-1h462 
injected mice, doxycycline was supplied in the 
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drinking water (100µg/ml doxycycline) or daily via 
intraperitoneal injection (i.p.) of 100 µg/mouse.  
Ethics Committee Approval 
All animal experiments were carried out in ac-
cordance with protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of Explora 
Biolabs (San Diego, USA, protocol number EB11-025) 
or the government of Unterfranken (Würzburg, Ger-
many, protocol numbers AZ 55.2-2531.01-17/08 and 
55.2-2531.01-76/13). 
L-DOPA turnover rate 
To compare the activity of mTyr the substrate 
(L-DOPA) turnover was measured over time by in-
crease of absorbance at 475 nm. A modified method of 
Hida et al. was used [19]. A549 cancer cells were in-
fected with the different rVACV strains at an MOI of 
0.1. One group was supplemented with 1µg/ml 
doxycycline while no doxycycline was added to the 
other. Twenty-four hours later, the supernatant was 
aspirated and the cells lysed in phosphate lysis buffer 
(32.5mM Na2HPO4-2H2O, 34,2mM KH2PO4, 1% Tri-
tonX, pH 6.8), transferred to a fresh 1.5 ml tube and 
centrifuged (10000 rpm) to remove cell debris. Protein 
concentrations were determined with standard Brad-
ford assay. From each normalized sample 180 µl of 
supernatant was transferred to a 96 well plate and 
co-incubated with 20 µl of a 10 mM L-DOPA (Sig-
ma-Aldrich) solution. The increase in absorbance at 
475 nm was measured for 2h every 10 min at room 
temperature in an absorbance reader (Tecan Sunrise, 
Mannedorf, Switzerland). The mean velocity (v) was 
defined as increase of optical density at 475nm 
(OD475nm) per time interval (0 - 120min).  
Determination of melanin amounts in cell 
cultures and tumor tissues 
Cell cultures 
The melanin content of different samples was 
determined by using a modified protocol of Hida et al. 
[19]. Infected A549 or PANC-1 cancer cells were 
trypsinized (1xTyrpsin + EDTA; PAA) until cells de-
tached. Trypsinization was stopped with growth me-
dium (total volume 1ml), transferred to a fresh 1.5ml 
tube and centrifuged (13000 rpm). Afterwards, the 
cells were washed with HBSS (PAA) followed by an-
other centrifugation (13000 rpm) step. The superna-
tant was discarded, the pellet resuspended in 1M 
NaOH and heated to 99°C for 10 min. After cooling 
down, 100 µl of each sample was transferred into a 96 
well plate and the OD475nm was determined in an ab-
sorbance reader (Tecan Sunrise). 
Quantification of melanin using (multispectral) 
optoacoustic tomography (MSOT) 
Tumor Xenografts 
Volumetric (three dimensional) MSOT (vMSOT) 
images of the excised tumors were taken ex vivo. The 
vMSOT system described in detail in [20] allows fast 
(high-throughput) imaging of the whole tumor vol-
ume by simultaneous detection of signals with 256 
sensors distributed on a spherical surface. Tumor 
images were acquired at 740, 760 and 780 nm, and 
subsequently averaged 200 times at each wavelength 
for noise reduction. The reconstructed 
three-dimensional images represent the optical ab-
sorption at each wavelength with an almost isotropic 
resolution of 200µm. The distribution of melanin spe-
cific absorption was then estimated by linearly 
un-mixing the multispectral images to a combination 
of melanin and deoxygenated hemoglobin. Indeed, 
the imaging wavelengths were chosen for efficiently 
un-mixing these two chromophores with known op-
tical absorption spectra. Because the melanin absorp-
tion is proportional to its concentration, the amount of 
melanin can be deduced from the un-mixed images. 
Tumor tissue homogenates 
Homogenates of these tumors were placed into 
an agarose phantom and measured at 700nm. Opto-
acoustic signal measurements were performed at dif-
ferent positions of the sample. The observed region 
consisted of 24 individual slices and had a total length 
of 11.5 mm. In a second position of the agarose 
phantom a tumor tissue homogenate containing no 
melanin was measured in parallel serving as back-
ground control. Optoacoustic signals over back-
ground were measured at a single wavelength of 700 
nm for each slice. The total signal per region of inter-
est (ROI) was calculated and arithmetically averaged 
for each sample. 
All experiments that were performed in this 
study were below the safety exposure limit for laser 
radiation in the near-infrared, which is 20mJ/cm2 for 
700nm, and even higher at higher wavelength. 
Magnetic Resonance Imaging (MRI) 
Tumor homogenates were imaged on a 7 Tesla 
small animal imaging system (Bruker BioSpec, Biller-
ica, USA). T1 relaxation time maps (rapid acquisition 
with refocused echoes [RARE]-T1+T2-map saturation 
recovery TR/TE, 5000-200/11-99ms, Field of view 5.5 
cm, matrix 256 x 256, slice thickness 1 mm, 8 slices 
interleaved, total imaging time 19 min 43 seconds) 
were acquired on 2-4 slices through sealed straws 
containing tumor homogenates. The straws were 
embedded in low melting agarose (5% in PBS) to 
prevent surface artifacts. The T1-values of each slice 
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were averaged from the calculated T1-values in each 
pixel of a manually drawn region of interest, which 
included the interior of the straw cross-section. 
R1-relaxation rates were calculated from the obtained 
T1 values (R1-relaxation rate=1/T1 value). 
Statistical analyses 
A two-tailed Student’s t test was used for statis-
tical analysis. A p value of ≤ 0.05 was considered sta-
tistically significant. 
Results 
rVACV marker gene expression in infected 
A549 lung carcinoma cells  
The vaccinia virus strains GLV-1h312, 
GLV-1h460 and GLV-1h462 (Fig. 1A) were tested for 
expression of the inserted marker genes. For this, 
A549 lung carcinoma cells were infected with these 
different rVACVs using an MOI of 0.1. Protein sam-
ples were collected after an incubation time of 24h in 
presence or absence of doxycycline (1 µg/ml) and 
analyzed by Western blot (Fig. 1B). Human beta-actin 
which served as a loading control was detected in 
each lysate. As expected, expression of the 25 kDa 
Tet-repressor could be detected in GLV-1h312 and 
GLV-1h462 infected cells, in the presence or absence 
of doxycycline (dox), while Ruc-GFP (64 kDa) was 
found only in GLV-1h460 infected A549 cells (Fig. 1B). 
The functionality of the tet-system was confirmed as 
well. Expression of regulated genes could only be 
detected in the presence of dox, when the conforma-
tional change of TetR resulted in dissociation from the 
tet-operator allowing transcription of the viral pro-
moter regulated expression cassette by the viral 
RNA-polymerase. The mRFP1 molecule (30 kDa) in-
serted into the TK locus of GLV-1h312, was detected 
solely in GLV-1h312 infected A549 cancer cells in 
presence of dox. GLV-1h462 infected A549 cells 
showed mTyr (70 kDa) expression in presence of dox 
but not when the inducer was absent. Lung carcinoma 
cells infected with GLV-1h460, which does not encode 
tetR, produced mTyr both in the absence or presence 
of dox. All three rVACV strains lead to expression of 
GusA, the E. coli beta-glucuronidase (60 kDa), inserted 
in the viral HA locus (Fig. 1A) in presence or absence 
of dox (Fig. 1B). Mock infected A549 cells served as 
negative control for the virus encoded marker pro-
teins. 
Melanin synthesis in melanogenic rVACV in-
fected A549 cancer cells 
To find the dox concentration at which mTyr ex-
pression was induced, GLV-1h462 infected A549 
cancer cells were incubated in the presence of in-
creasing dox concentrations (0, 0.01, 0.05, 0.1, 0.5 and 1 
µg/ml) (Fig. 2A). Mock infected and GLV-1h312 in-
fected A549 lung carcinoma cells served as a negative 
control for melanin production and showed low 
background levels as indicated by optical density 
measurements at 475nm (OD475). Non-infected A549 
cells had an almost constant OD475 of about 0.1 ± 0.01 
regardless of the applied dox concentration. The 
somewhat lower OD475 of GLV-1h312 infected cells 
compared to mock infected cells can be explained by 
reduced cell numbers due to viral infection. In case of 
GLV-1h460 infected A549 cells, which produced 
melanin in a constitutive manner (Fig. 1A and B), a 
nearly constant high absorbance of 0.28 ± 0.01 at 475 
nm could be detected regardless of the amounts of 
dox in the medium. In contrast, GLV-1h462 infected 
A549 cancer cells showed a low optical density at a 
dox concentration of 0 µg/ml (0.087 ± 0.003) and 0.01 
µg/ml (0.103 ± 0.014). At a dox level of 0.05 µg/ml a 
significant increase (p < 0.001) in OD475 (0.284 ± 0.009), 
and therefore melanin synthesis, was detected. This 
dox concentration (0.05 µg/ml) seemed to saturate the 
inducible system in vitro as no further increase in 
OD475 with higher dox concentrations was observed. 
 
Figure 1: rVACV mediated expression of proteins in A549 cancer cells. A) Map of relevant insertions into the genome of the different rVACV strains. B) Western blot 
analysis of viral marker (TetR, RFP, GusA, Ruc-GFP, mTyr) expression in rVACV infected A549 lung carcinoma cells in presence or absence of dox.  
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In addition to the absorbance measurements, the 
velocity of L-DOPA turnover, as a measure of tyrosi-
nase activity, of GLV-1h460 and GLV-1h462 infected 
A549 cells 24 hours post virus infection (hpvi) was 
determined (Fig. 2 B). While lysates of GLV-1h460 
infected A549 cancer cells showed no significant dif-
ference in mean velocity (v) in the presence (0.089 ± 
0.010 ΔOD475/10min) or absence (0.091 ± 0.010 
ΔOD475/10min) of dox, cell lysates of GLV-1h462 in-
fected A549 cells showed a significantly (p ≤ 0.01) 
higher L-DOPA turnover rate in presence (0.074 ± 
0.006 ΔOD475/10min) than in absence (0.000 ± 0.000 
ΔOD475/10min) of dox. 
Enhanced spreading capacity of non-induced 
not tyrosinase expressing rVACV GLV-1h462 
Constitutive production of melanin resulted in 
reduced viral replication as well as decelerated tumor 
regression when compared to non-melanogenic 
rVACV [7]. To analyze whether we can achieve better 
replication and spreading in the non-induced state, 
A549 cells were infected with GLV-1h460 and 
GLV-1h462 in the presence or absence of 1 µg/ml dox 
(Fig. 3A and B). Plaques of non-induced and hence not 
melanin synthesizing GLV-1h462 were bigger than 
plaques of constitutively melanin producing 
GLV-1h460 or those of dox-induced melanogenic 
GLV-1h462 (Fig. 3A). Quantitative analysis of the 
maximum plaque diameters of each group (Fig. 3B) 
revealed that the maximum plaque diameters of 
non-induced not melanin producing GLV-1h462 in-
fected A549 cells were significantly (p < 0.001) bigger 
(maximum diameter: 124 ± 32µm) than those of in-
duced melanin synthesizing GLV-1h462 infected cells 
(71 ± 31µm) or GLV-1h460 infected A549 in the ab-
sence (67 ± 24µm) or presence (62 ± 22µm) of dox. No 
significant plaque-diameter difference between mela-
nin producing plaques were observed. Similar results 
were observed in PANC-1 tumor cells (data not 
shown). In addition to the enhanced spreading ca-
pacity a significantly better oncolytic potential in 
A549 (Fig. 3C) at 48, 72 and 96 hpvi and in PANC-1 
(Fig. 3D) cells at 72 and 96 hpvi of not induced and not 
melanin-producing GLV-1h462 was demonstrated. 
Furthermore, a higher replication rate (Supplemen-
tary Fig. S1) was observed. 
Doxycycline exposure inversely correlates 
with oncolytic potential of GLV-1h462 
In a clinical setting, the best synergistic effects of 
the diagnostic and the therapeutic potential of the 
melanogenic rVACV should be achieved when the 
production of melanin does not interfere with the 
oncolytic potential or is reduced to a minimum. Since 
constitutive melanin production obviously reduced 
the oncolytic potential (reduced plaque size upon dox 
induction in Fig. 3A, B), it was necessary to evaluate 
the therapeutic effects of the virus in a setting of tran-
sient doxycycline exposure. It was expected that the 
shorter the exposure to doxycycline, the higher the 
oncolytic potential would be. 
Cells were therefore infected with a defined 
number of plaque forming units of GLV-1h462 and 
control strains respectively. The doxycycline con-
taining overlay medium that was replaced with 
dox-free medium at different times post viral infection 
(at 0, 2, 6, 8, 24, 48 and 72 hpvi respectively). Conse-
quently, tyrosinase (and therefore mela-
nin)-production was transient. The infection was 
stopped simultaneously at 72 hours post viral infec-
tion and the maximum plaque diameter for at least 25 
plaques/virus strain and dox-exposure time was 
measured (Fig. 4). 
 
 
Figure 2: Induction of tyrosinase expression in GLV-1h462 infected A549 cells A) Absorbance measurements at 475nm of cell lysates from rVACV infected A549 cells 
incubated with different dox concentrations. Significantly higher optical density at 475nm was obtained from GLV-1h462 infected A549 cells at a concentration of 0.05 µg/ml 
compared to 0.01 µg/ml doxycycline. No significant influence of dox on OD475nm of GLV-1h460, GLV-1h312 or mock infected A549 cancer cells. B) Mean velocity of L-DOPA 
turnover in A549 cell lysates from cells infected with melanogenic rVACV in presence or absence of dox. Significantly higher velocity of L-DOPA turnover in dox induced than 
non-induced GLV-1h462 infected A549 cells (p < 0.01). No significant dox-dependent difference in velocity in GLV-1h460 infected cells.  
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Figure 3: Oncolytic activity of inducible melanogenic rVACV strains. Photography A) and quantitative evaluation B) of plaque sizes in A594 cancer cells infected with 
melanogenic rVACV incubated in presence (+) or absence (-) of 1 µg/ml dox. Significantly larger mean maximum plaque diameter of non-induced not melanin producing 
GLV-1h462 infected A549 cancer cells compared to induced melanogenic GLV-1h462 infected A549 cells or GLV-1h460 infected A549 cancer cells (p < 0.001; n ≥ 50). 
MTT-Assay of A549 C) and PANC-1 D) cancer cells infected (MOI 0.01 or MOI 0.1) with the constitutively melanin synthesizing GLV-1h460, the non-melanogenic GLV-1h68 and 
GLV-1h312 and the dox inducible melanogenic GLV-1h462. The control rVACV showed no significant difference in oncolysis, regardless of absence or presence of doxycycline 
(1µg/ml). In contrast, the inducible melanogenic GLV-1h462 infected groups showed a significantly higher oncolysis rate 48, 72 and 96 hpvi in A549 cells and 72 and 96 hpvi in 
PANC-1 cells in the absence of dox (***p <0.001; **p <0.01, *p <0.5). 
 
Figure 4: Effects of transient doxycycline induction on inducible melanogenic VACV based oncolysis. Quantitative evaluation of plaque sizes in CV-1 cells infected 
with inducible melanogenic GLV-1h462, constitutively melanogenic GLV-1h460 and non-melanogenic GLV-1h312 incubated in presence (w/) or absence (w/o) of 1 µg/ml dox for 
72 hours. CV-1 cells infected with GLV-1h462 were incubated for 2, 6, 8, 24, 48 and 72 hours with 1 µg/ml dox respectively. Data represent the average maximum plaque 
diameter plus standard deviation of at least 25 plaques/virus strain and dox exposure time. 
 Theranostics 2015, Vol. 5, Issue 10 
 
http://www.thno.org 
1052 
 
Figure 5: Viral activity and oncolytic potential of tested rVACV in PANC-1 xenograft bearing nude mice A) Tumor volume measurements of PANC-1 tumors 
untreated (PBS) or treated with GLV-1h460, GLV-1h312 and GLV-1h462 (n=3-5). Significant smaller tumor volume of uninduced non-melanogenic GLV-1h462 colonized 
PANC-1 tumors 55 dpvi compared to GLV-1h460 infected tumors and 63 dpvi compared to dox induced melanin synthesizing GLV-1h462 injected PANC-1 tumor bearing mice 
(p <0.05). B) Escherichia coli beta-glucuronidase activity assay of blood serum samples of PANC-1 xenograft bearing mice injected with GLV-1h462. GusA-activities are normalized 
by tumor volume as a correction factor.  
 
As postulated, the negative effects on viral rep-
lication and spreading upon induction of mela-
nin-synthesis were reversible. The longer the time 
interval without doxycycline induction the closer the 
therapeutic potential (max. plaque diameter) was to 
the control without dox or the non-melanogenic con-
trol strain (GLV-1h312). In this experiment 
co-incubation with dox for 8h or more led to signifi-
cant (p <0.05) smaller plaque diameters compared to 
GLV-1h462 infected cells, which were not incubated 
with dox or to dox treated GLV-1h312 control virus 
infected cells. When compared to the constitutively 
melanin producing vaccinia virus strain GLV-1h460, 
all plaques of GLV-1h462 infected cells showed sig-
nificantly larger plaques, except the permanent (72 h) 
dox induced GLV-1h462 infected cells. 
Enhanced oncolytic potential of non-induced 
and therefore not melanogenic rVACV 
GLV-1h462 
Following the characterization in cell cultures we 
analyzed the effect of the different virus strains on 
xenograft tumor regression in mice. Therefore, nude 
mice bearing PANC-1 tumors (~200mm³) were in-
jected with GLV-1h312, GLV-1h460 and GLV-1h462 
respectively (Fig. 5). Five GLV-1h462 injected mice 
received 100 µg/ml dox in the drinking water while 
the other mice (n = 5 per group) did not receive dox 
supplement. The tumor growth over time showed 
that the non induced GLV-1h462 infected tumors had 
a similar tumor volume as non-melanogenic 
GLV-1h312 treated tumors. Also, the tumor volume in 
those mice decreased over time. 
In contrast, the dox treated, melanin synthesiz-
ing GLV-1h462 injected PANC-1 xenograft bearing 
nude mice, exhibited higher tumor volumes, which 
were similar to those observed in the melanin pro-
ducing GLV-1h460 injected group. Moreover, both 
groups showed a slightly increasing tumor volume, 
which resulted in a significant difference compared to 
the not induced GLV-h1462 injected group at day 55 
post viral injection (dpvi) compared to GLV-1h460 
injected mice and 63 dpvi concerning the induced 
melanin producing GLV-1h462 injected tumor bear-
ing mice (Fig. 5A). A better therapeutic efficiency in 
uninduced GLV-1h462 colonized tumors was also 
observed in A549 tumor bearing mice (Supplemen-
tary Fig. S2A). Furthermore, the median tumor sizes 
of GLV-1h68 injected mice were very similar regard-
less of exposure to dox in this tumor model. There-
fore, we concluded that dox had neither a negative 
influence on viral activity nor an anticancer effect at 
these concentrations.  
To further investigate in vivo whether the viral 
replication and oncolysis of GLV-1h462 was im-
proved if expression of the melanogenic enzyme 
mTyr was not induced, blood serum of PANC-1 tu-
mor bearing mice infected with GLV-1h462 with or 
without induction with dox was collected. Subse-
quently, the E. coli beta-glucuronidase levels, as 
marker for viral replication [18], was determined (Fig. 
5B). At 56 dpvi a difference between the E. coli be-
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ta-glucuronidase levels per mm³ tumor volume of 
non-induced GLV-1h462 injected mice in comparison 
to induced GLV-1h462 could be detected. Addition-
ally to the blood sera of PANC-1 xenograft bearing 
mice, the beta-glucuronidase levels in blood sera of 
A549 tumor bearing mice was measured (Supple-
mentary Fig. S2B). The amounts of enzyme per tumor 
volume at 49 and 56 dpvi were significantly higher in 
case of non-induced GLV-1h462 infected A549 tumor 
bearing mice (p ≤ 0.05). This indicated an increased 
oncolytic activity at these time points. 
Imaging of induced melanogenic rVACV with 
MRI and vMSOT technologies 
We reported earlier that rVACV dependent 
melanin production in infected tumor cells was visu-
alized with magnetic resonance imaging (MRI) and 
multispectral optoacoustic tomography (MSOT) [7]. 
Here, we investigated if the dox inducible melano-
genic reporter system GLV-1h462 is also suitable for 
both imaging technologies. Moreover, we wanted to 
know how early melanin could be detected by either 
technology after dox induction in mice. We therefore 
excised A549 tumor xenografts at different times after 
the induction with dox and analyzed the MRI and 
volumetric MSOT (vMSOT) signals from these sam-
ples. Already 4 days post induction (dpi) clear mela-
nin dependent vMSOT-signals were detected which 
were confirmed by visual inspections revealing the 
production of melanin (Fig. 6). Moreover, the melanin 
specific signals in vMSOT increased over time. The 
last time point measured (18dpi) showed the highest 
signal intensity while the non-induced GLV-1h462 
infected A549 xenografts showed no or very little 
melanin specific signal. In PANC-1 tumors, we de-
tected a melanin signal in GLV-1h460 and in induced 
GLV-1h462 colonized xenografts while no or very 
little melanin-dependent vMSOT-signal was observed 
in GLV-1h312 and uninduced GLV-1h462 tumors 
(Supplementary Fig. S3A). 
 
Figure 6: Ex vivo vMSOT-images and photographs of GLV-1h462 infected A549 tumor xenografts with or without doxycycline induction. At each time point 
the same two excised A549 tumors of identical treatment are shown as 3D-reconstruction vMSOT images (upper 2 panels; pink represents tumor tissue; black represents 
melanin in tumor tissue), vMSOT maximum intensity projection images (middle 2 panels) and photographic pictures (lower 2 panels). Melanin specific signal intensity in the 
vMSOT images is presented as heat map. Left and right columns show the non-induced group (-), middle columns show tumors of doxycycline treated mice (+). Each column 
represents one time point after induction with doxycycline. The orientation of the tumors is not identical between the images. 
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To further characterize the increasing melanin 
signal more quantitatively these tumors were ho-
mogenized and analyzed by MSOT and MRI (Fig. 7). 
In both cases, the received signals increased over time 
in the presence of dox for GLV-1h462 colonized tumor 
homogenates. The optoacoustic signal (Fig. 7A) of 
induced GLV-1h462 injected tumors was undistin-
guishable from the controls at the beginning of the 
dox induction and then increased steadily. Lysates of 
non-induced GLV-1h462 colonized tumors had opto-
acoustic signals that were in the range of the 
non-melanin producing controls even at the last time 
point. In contrast, lysates of GLV-1h460 colonized 
tumors contained much more melanin at the begin-
ning of the experiment (2 days post start of the dox 
treatment). The somewhat higher melanin concentra-
tion at 18 days post dox treatment could be explained 
with the continuous production of melanin in those 
tumors. 
A very similar observation was made for the R1 
relaxation rates that were obtained from the very 
same lysates (Fig. 7B). The signal (R1 relaxation rate) 
increased over time in the GLV-1h462 containing 
samples upon dox induction.  
Quantification of the melanin related max. 
MSOT signal intensities of PANC-1 tumors revealed 
significantly higher MSOT signal intensities in mela-
nin synthesizing rVACV colonized tumors in com-
parison to non-melanin-producing vaccinia virus in-
fected PANC-1 tumors (Supplementary Fig. S3B). 
We also observed correlation in increase be-
tween the melanin dependent optoacoustic signal 
intensities and the increase in R1 relaxation rate ob-
tained by MRI (R² = 0.49) (Fig. 7C) which means 
melanin could be used adequately in both imaging 
modalities.  
 
 
Figure 7: Evaluation of melanin amounts with MRI and optoacoustic imaging. Homogenized tissues of infected or PBS treated control A549 tumors analyzed by 
optoacoustic imaging at 700nm A) and MRI B) (n = 2-4). Correlation C) of MRI and MSOT signal intensities of the values in A) and B) (R² = 0,49).  
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Discussion 
Here, we showed that exogenously controlled 
melanin synthesis in vaccinia virus colonized tumor 
xenografts was feasible, resulting in improved syner-
gistic effects of therapy and diagnosis. Doxycycline 
induction resulted in enhanced (v)MSOT and MRI 
signals. At the same time the therapeutic outcome of 
the inducible rVACV could be enhanced, when com-
pared to constitutively melanin producing rVACV 
strains.  
For induction of melanin production, we insert-
ed the tet-regulated gene expression system compo-
nents into the rVACV genome [15]. The system can be 
induced with doxycycline, a tetracycline derivate [21]. 
Doxycycline is a well-established and tolerated anti-
biotic [22]. Recent studies suggested an anti-cancer 
effect of tetracyclines due to inhibition of the matrix 
metalloproteinases (MMP) family. MMPs play an 
important role in tumor invasion and metastases 
formation by degradation of the tumor matrix. Addi-
tionally, MMPs are thought to activate tumor growth 
factors α and β (TGF-α and –β), epidermal growth 
factor (EGF) and vascular endothelial growth factor 
(VEGF) [23]. In the study presented here, no differ-
ence concerning tumor volume between 
non-melanogenic GLV-1h68, in combination with 
doxycycline or GLV-1h68 injected mice not treated 
with doxycycline could be observed. Reduced levels 
of MMPs in the tumor tissue might lead to less tumor 
growth but it also reduces the viral distribution 
through a denser tumor matrix [24], which might 
compensate an adjuvant anti-cancer effect of doxycy-
cline in combination with rVACV. 
We have shown that the vaccinia virus construct 
GLV-1h462 leads to production of melanin in infected 
cell cultures and in mice but only after doxycycline 
exposure in A549 and PANC-1 cancer cells or tumors. 
The amounts of synthesized melanin in A549 tumors 
4 days after induction was sufficient to generate a 
clear signal detectable with MRI or MSOT. We 
showed also that the amounts of melanin and there-
fore the signal intensities of both imaging modalities 
were increasing over time. Even though all of imaging 
experiments in this study were performed ex vivo, we 
do not have reason to believe that in vivo experiments 
would result in dramatic changes in signal intensities 
over background as we could show previously that 
melanin production can be detected in vivo by both 
MRI and MSOT [7]. 
Furthermore, we observed that plaque formation 
in induced melanin synthesizing GLV-1h462 infected 
tumor cells resulted in significantly smaller plaques 
than those of non-induced non-melanogenic 
GLV-1h462 infected cells, suggesting a greater onco-
lytic potential. Indeed, non-induced GLV-1h462 had 
enhanced oncolytic effects compared to doxycy-
cline-induced melanogenic GLV-1h462 in injected 
mice. The inhibition of mTyr expression led to in-
creased viral replication.  
Previously, we observed that rVACV-mediated 
constitutive melanin production slowed down tumor 
regression [7]. Interestingly, Cunha et al. showed in 
cell cultures that due to melanogenesis in B16F10 
murine melanogenic melanoma cell lines the levels of 
reactive oxygen species (ROS) increased, which led to 
cell cycle arrest [25]. The cell damage resulting from 
production of ROS might also slow down viral repli-
cation, either directly or through inhibitory effects in 
the host cell. Another reason for the reduced replica-
tion of melanogenic rVACV could be the depletion of 
L-tyrosine inside the cells due to the increased tyro-
sine consumption for virus-mediated melanin syn-
thesis. Depletion of L-tyrosine consequently would 
reduce protein synthesis, which would negatively 
influence viral replication. While production of mela-
nin can inhibit the growth of individual melanin 
producing cells, to our knowledge melanin itself has 
no systemic toxicity. Intermediates in melanin bio-
synthesis are reported to have toxicity, which in the-
ory, could be released during virolytic oncolysis 
[26,27]. Additionally, melanin is known to bind to a 
number of potentially toxic drugs and substances, 
which could result in accumulation of those com-
pounds to toxic levels over time [28]. At this time, we 
cannot exclude any toxic effects when melanin pro-
duction is induced by expression of virus-encoded 
tyrosinase, but we assume that the risk is rather low as 
melanin is naturally produced in many different or-
gans of many different species. Also, in our studies, 
we have not detected side effects or adverse events 
that would indicate major health risks. 
To avoid decrease in viral replication due to 
melanin production, but preserve the advantages 
given by melanin imaging we constructed an induci-
ble melanogenic rVACV strain. Chen et al. showed 
previously that the replication rate of rVACV in-
versely correlated with the amount of inserted marker 
genes, which are expressed [29]. Likewise, the viral 
replication should be enhanced if melanin production 
is not induced, a finding we observed in our experi-
ments. 
In a clinical setting, the melanin production 
needs to be induced for imaging purposes (or for laser 
mediated thermotherapy – see below). When suffi-
cient melanin is produced, the dox supplementation 
would stop and the virus replication may gain speed 
again. In this study, we did not test in how far the 
short-term exposure to dox would influence the 
therapeutic outcome in vivo. However, we could show 
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in cell cultures that the duration of doxycycline ex-
posure inversely correlates with the plaque size, and 
therefore oncolytic potential, of the inducible mela-
nogenic rVACV (Fig. 4). We can therefore assume that 
short-term dox treatment in patients will not decrease 
the therapeutic effects.  
The synthesized melanin content may be poten-
tially monitored with the vMSOT system employed 
herein, which can operate as a hand-held probe 
providing sufficient contrast and nearly isotropic res-
olution for depths beyond 1cm inside tissues [20], in 
the clinics. Accordingly, indications with surface-near 
rVACV-colonized tumor lesions can be monitored 
using optoacoustic imaging systems, whereas coloni-
zation in deeper tissues would require MRI. 
A further application of the novel rVACV strain 
is the combination of induced melanin production 
with laser-induced thermotherapy. This may correct 
the slower tumors response upon melanin-dependent 
absorption of near infrared laser light followed by 
thermal induced cell killing (Stritzker and Kirscher, in 
preparation).  
Additionally, safety is still a major concern in 
oncolytic viral therapy [30]. Hagen as well as Grigg et 
al. introduced tet-mediated inducible systems for vac-
cinia virus based vectors to safely stop viral replica-
tion in the host if needed [31,32]. If our system is in-
duced, virus replication is not stopped completely but 
significantly reduced. This melanogenesis associated 
“metabolic attenuation” can be used as an additional 
regulatory tool for experiments and in the clinic. 
Conclusion 
With the inducible melanogenic rVACV system 
presented here we were able to image tumor tissues 
with MRI or MSOT and in addition increased the 
therapeutic potential of the novel melanogenic onco-
lytic rVACV based reporter system.  
Supplementary Material  
Figures S1-S3, Table S1. 
http://www.thno.org/v05p1045s1.pdf 
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